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Abstract
Background—The relationship between efavirenz use and suicidality is not well defined.
Objective—Compare time to suicidality with efavirenz-containing versus efavirenz-free 
antiretroviral regimens for initial treatment of HIV.
Design—Participant-level data were analyzed from four AIDS Clinical Trials Group (ACTG) 
antiretroviral-naïve studies conducted from 2001 to 2010. Within each study, participants were 
randomly assigned to an efavirenz-containing (n=3241) or efavirenz-free regimen (n=2091).
Setting—ACTG sites; 74% enrolled in the United States.
Patients—Antiretroviral-naïve participants.
Intervention—Efavirenz versus efavirenz-free regimens.
Measurements—Suicidality was defined as suicidal ideation, attempted or completed suicide. 
Groups were compared with a hazard ratio (HR) and 95% confidence interval (CI) estimated from 
a Cox model stratified by study.
Results—73% were men, median age was 37 years; 32% had documented psychiatric history or 
received psychoactive medication within 30 days prior to study entry. Median follow-up was 96 
weeks. Suicidality incidence per 1000 person-years was 8.08 (47 events) in the efavirenz group 
and 3.66 (15 events) in the efavirenz-free group, HR: 2.28 (95% CI: 1.27 to 4.10, p=0.006). 
Incidence of attempted or completed suicide was 2.90 (17 events) and 1.22 (5 events) in the 
efavirenz and efavirenz-free groups, respectively, HR: 2.58 (95% CI: 0.94 to 7.06, p=0.065). Eight 
suicide deaths in the efavirenz group and one in the efavirenz-free group were reported.
Limitations—There was not a standardized questionnaire regarding suicidal ideation or attempt. 
Efavirenz was open-label in three of four studies.
Conclusions—Initial treatment with an efavirenz-containing antiretroviral regimen was 
associated with a two-fold increased hazard of suicidality compared to a regimen without 
efavirenz.
Keywords
efavirenz; suicide; suicidal ideation; suicidal behavior; HIV; adverse event; psychiatry
Introduction
Efavirenz is a preferred non-nucleoside reverse transcriptase inhibitor (NNRTI) for 
treatment of HIV (1-4). Although generally safe and effective, efavirenz is associated with 
central nervous system side effects (5-8), and prescribing information contains warnings of 
rare but serious psychiatric experiences, including suicide, but also notes that a causal 
relationship cannot be determined from post-marketing reports (5). Likewise, published 
cases and case series report suicidal thoughts or behavior with efavirenz (9-17). A recent 
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literature review stated that clear evidence of association between efavirenz and suicide was 
not available, and thus psychiatric history should not exclude patients from efavirenz 
treatment (18).
Given the widespread use of efavirenz and uncertainty regarding its relationship to suicide, 
suicide attempt or suicidal ideation, we report here an AIDS Clinical Trials Group (ACTG) 
cross-protocol analysis of four studies in which participants were randomly assigned to an 
initial efavirenz-containing or efavirenz-free antiretroviral regimen. Our primary goal was to 
compare the hazard of suicidality between participants assigned to an efavirenz-containing 
versus efavirenz-free antiretroviral regimen for initial treatment of HIV-1, a potential safety 
issue not reported in the original studies.
Methods
Study design and participants
Individual-level data from HIV-1-infected antiretroviral-naïve participants in ACTG studies 
conducted from 2001 to 2010 with random assignment to an efavirenz-containing or 
efavirenz-free regimen were included in this pre-specified retrospective cross-study analysis. 
Four studies met these criteria: A5095 (ClinicalTrials.gov registration number: 
NCT00013520) (19, 20), A5142 (NCT00050895) (21), A5175 (NCT00084136) (22), and 
A5202 (NCT00118898) (23). Except for nucleoside analogue choice in A5142, components 
of the antiretroviral regimen were randomly assigned.
The studies varied by antiretroviral regimen and slightly by duration and eligibility criteria 
(Table 1), though each study excluded participants with substantially abnormal baseline 
laboratory values. Histories of suicidal ideation or attempt were not exclusion criteria. 
Studies A5095 and A5202 enrolled in the United States and Puerto Rico; A5142 enrolled in 
the United States and South Africa. Study A5175 enrolled participants from nine countries 
in North and South America, the Caribbean, Africa, and Asia.
Study protocols required report of signs, symptoms, or diagnoses at each visit, recorded with 
both open-text and data-entry codes. In A5175, diagnosis reporting instructions included 
specific codes for suicidality; the other studies used general psychiatric event codes (e.g. 
“psychiatric disorder, specify”) plus open-text description. Each study required reporting of 
severe and life-threatening graded signs or symptoms per the Division of AIDS grading 
table (24), as well as any sign or symptom, regardless of grade, that led to change in study 
treatment; diagnoses were not graded. Furthermore, study A5142 required report of all 
moderate signs or symptoms, A5095 and A5202 required all moderate central nervous 
system symptoms. Site institutional review boards approved each study; participants 
provided written informed consent.
Randomization
Each study used permuted-block randomization; stratification factors and treatment arms are 
listed in Table 1. Efavirenz was formulated as one 600-mg pill given once daily, with three 
200-mg pills given initially in A5095. Efavirenz assignment was open-label in A5142, 
A5175 and A5202, and was blinded and placebo-controlled in A5095 prior to a data safety 
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and monitoring board (DSMB) recommendation to unblind efavirenz. The DSMB released 
recommendations mid-study regarding inferior efficacy in the efavirenz-free arm of A5095 
(February 20, 2003) and A5175 (May 23, 2008), after which participants in the efavirenz-
free arms were given the option to switch treatment (19, 22).
Outcomes
The primary outcome of this cross-study analysis was suicidality, defined as suicidal 
ideation, attempted, or completed suicide, and identified from signs, symptoms, diagnoses, 
adverse events, and death data via Medical Dictionary for Regulatory Activities (MedDRA) 
coding version 15.0. Pre-specified MedDRA preferred terms were: “Completed suicide”, 
“Suicide attempt”, “Intentional overdose”, “Multiple drug overdose intentional”, “Poisoning 
deliberate”, “Suicidal ideation”, “Suicidal behaviour”, and “Depression suicidal”. Attempted 
or completed suicide was a secondary outcome. Clinical investigators, blinded to treatment 
and prior adverse events, independently reviewed death data categorized as suicide, 
substance abuse, homicide, accident, unknown cause, or other cause (e.g. infection, cancer, 
organ failure); a secondary outcome included suicidality or fatal injury attributed to 
potentially-related causes (substance abuse, homicide or accident).
Covariates
Each study protocol required report of prescription medication ongoing within 30 days prior 
to entry (denoted “recent pre-study”); pre-study psychoactive and antidepressant 
medications were identified from a medication list on the National Institute of Mental Health 
website (25). Psychiatric history was defined as any event in the MedDRA system organ 
class “Psychiatric disorders”, and depression-related events were classified according to 
review of psychiatric events data by a psychologist. Pre-study psychiatric measures included 
psychiatric event history, recent psychoactive medication, depression-related event history, 
and recent antidepressant medication; presence of event history or pre-study medication was 
combined into one covariate. Additional a priori baseline covariates included: geographic 
region, sex, race or ethnic group, age, pre-treatment CD4 count, history of AIDS-defining 
event, and history of injection drug use (IDU); pre-treatment HIV-1 RNA, body weight, and 
body mass index (BMI) at study entry were evaluated post hoc (Appendix Table 1). 
Analysis of race or ethnic group was limited to white, black, and Hispanic from the United 
States due to potential social-ethnic differences between countries and low frequencies in 
other groups, and was self-reported and classified according to NIH categories. Covariate 
misclassification was possible; for example history of psychiatric events or IDU could have 
been undisclosed or under-reported.
Statistical analysis
The primary analysis approach was intent-to-treat (ITT). Participant-level data were 
analyzed according to randomized treatment allocation, with follow-up from randomization 
to last on-study contact or death; all follow-up in A5095 and A5175 was censored after a 
DSMB recommendation related to the efavirenz comparison (denoted “ITT DSMB”). In 
sensitivity analysis, follow-up included time from randomization to last on-study contact or 
death, regardless of DSMB recommendations (denoted “ITT”); deaths are summarized using 
the ITT approach. As-treated analyses excluded participants who never started treatment and 
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included follow-up from treatment-initiation through the earliest of: discontinuation of the 
assigned efavirenz-containing or efavirenz-free strategy +28 days for washout, 
discontinuation of all antiretroviral therapy +28 days, or last on-study contact (denoted “as-
treated”). A sensitivity approach further censored as-treated follow-up at the time of DSMB 
recommendations (denoted “as-treated DSMB”). Antiretroviral modifications were allowed 
for reasons such as toxicity, virologic failure, or DSMB recommendations. Missing baseline 
data were rare (<1%), thus covariate-adjusted analyses used a complete-case approach.
Crude incidence rate was calculated as the number of cases per total person-years (PY) at-
risk, presented as events per 1,000 PY. Incidence rate difference (IRΔ) between treatment 
groups was quantified by a Mantel-Haenszel estimate stratified by study; with a 95% 
confidence interval computed using a rare-events variance estimator (26). The primary 
endpoint, time to suicidality, is presented with cumulative incidence curves, and compared 
between groups with Gray's test (27), stratified by study, with non-suicide death considered 
a competing risk. Estimated efavirenz and baseline covariate associations were quantified by 
a hazard ratio (HR) from a Cox proportional hazards model stratified by study. Modification 
of efavirenz association by covariates was evaluated with interaction terms. The Cox model 
proportional hazards assumption was evaluated with a piece-wise constant hazard with time 
(at ≤24 weeks; >24 weeks), and with a log-transformed time variable; the proportional 
hazards assumption was not violated. An incidence rate ratio for the efavirenz association 
was estimated from an exact Poisson model stratified by study, to evaluate sensitivity of the 
Cox model to low event frequencies. Analyses were conducted two-sided with a significance 
level of 0.05, without adjustment for multiplicity, in SAS version 9.2 and 9.3 (phreg, 
genmod, SAS Institute, Cary, NC) and in R version 2.15.1 competing risks package 
(cmprsk, http://www.r-project.org/).
Role of the funding source
The National Institute of Allergy and Infectious Diseases funded all four studies and this 
combined data analysis. Industry sponsors provided most antiretroviral medications, 
including efavirenz, and served as members of individual study teams, but were not involved 
with this analysis.
Results
Participant characteristics and study follow-up
In total, 5332 antiretroviral-naïve participants were randomly assigned to an initial 
efavirenz-containing regimen (n=3241) or efavirenz-free regimen (n=2091). At entry, 
median age was 37 years, 73% were men, 8% reported history of IDU, 13% had received 
recent pre-study psychoactive medication, 10% had received antidepressant medication, and 
32% had documented psychiatric history or recent pre-study psychoactive medication use. 
Through randomization, baseline characteristics were balanced between groups (Appendix 
Table 1). Median (Q1-Q3) follow-up was 96 (62-132) weeks for the primary analysis; the 
efavirenz and efavirenz-free groups had a similar length of follow-up within each study 
(Table 1).
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Suicidality: suicidal ideation, attempted or completed suicide
In the primary analysis, suicidality was reported for 62 participants; attempted or completed 
suicide accounted for 36% (17/47) of cases in the efavirenz group, and 33% (5/15) in the 
efavirenz-free group. During ITT follow-up, suicidality was reported for 83 participants, 
43% (27/63) of cases in the efavirenz group and 35% (7/20) in the efavirenz-free group 
involved attempted or completed suicide.
Incidence of first suicidality event was 8.08 per 1000 PY (47 events) in the efavirenz group 
and 3.66 (15 events) in the efavirenz-free group (stratified IRΔ 4.62 per 1000 PY, 95% CI: 
1.62 to 7.62). Time to suicidality was shorter in the efavirenz group; while time to non-
suicide death did not differ significantly between groups (Figure 1). The efavirenz 
association with time to suicidality did not differ significantly by study (Figure 2).
Participants in the efavirenz group had greater hazard of suicidality compared to the 
efavirenz-free group, (HR 2.28, 95% CI: 1.27 to 4.10, p=0.006). The estimated efavirenz 
association appeared larger in the first 24 weeks, with HR (95% CI) of 3.69 (1.41, 9.63) 
versus 1.54 (0.71, 3.34) beyond 24 weeks; this difference was not statistically significant 
and did not violate the proportional hazards assumption (p=0.165, continuous log-
transformed time p=0.24). Increased hazard of suicidality with efavirenz was observed 
across multiple sensitivity analyses (Table 2). In a secondary analysis of time to suicidal 
ideation, attempted or completed suicide, or death attributed to substance abuse, homicide, 
or accident, incidence was 9.28 (54 events) and 4.64 per 1000 PY (19 events) in the 
efavirenz and efavirenz-free groups, respectively (stratified IRΔ 4.84 per 1000 PY, 95% CI: 
1.59 to 8.10), with an estimated two-fold higher hazard in the efavirenz group (HR 2.06, 
95% CI: 1.21 to 3.50, p=0.007).
Attempted or completed suicide
In a secondary ITT DSMB analysis, the outcome was restricted to attempted or completed 
suicide (Appendix Figure 1); incidence was 2.90 per 1000 PY (17 events) in the efavirenz 
group and 1.22 (5 events) in the efavirenz-free group, (stratified IRΔ 1.86 per 1000 PY, 95% 
CI: 0.03 to 3.69). The ITT DSMB analysis of association between efavirenz and time to 
attempted or completed suicide resulted in an estimated HR of 2.58 (95% CI: 0.94 to 7.06, 
p=0.065). Results from the ITT sensitivity analysis reached statistical significance (HR 2.56, 
95% CI: 1.10 to 5.92) while the as-treated result was not significant (HR 2.24, 95% CI: 0.88 
to 5.69) (Table 2).
Participant characteristics and hazard of suicidality
In a multivariable analysis, the following covariates were significantly associated with an 
increased hazard of suicidality, HR (95% CI): efavirenz compared to efavirenz-free 
assignment, 2.08 (1.16, 3.75), p=0.014, history of IDU, 2.26 (1.15, 4.46), p=0.019, 
documented psychiatric history or recent pre-study psychoactive medication, 4.07, (2.32, 
7.13), p<0.001, and lower baseline weight, 2.69 (1.25, 5.79) for <60 kg, 1.21 (0.64, 2.29) for 
60-<80 kg, reference group ≥80 kg, p=0.022 (Appendix Table 2). In a sensitivity analysis 
including all study follow-up (ITT), efavirenz assignment, history of IDU, and documented 
psychiatric history were again associated with an increased hazard of suicidality; 
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furthermore, younger age, but not body weight, was associated with an increased hazard of 
suicidality. Associations with suicidality limited to United States participants were similar 
(Supplement). Documented psychiatric history included suicidality, which was infrequent, 
with 16 pre-study suicidality cases (0.5%) in the efavirenz group and 9 (0.4%) in efavirenz-
free group; 5/16 and 1/9 of these participants experienced suicidality during ITT follow-up, 
respectively.
Causes of death
Incidence of suicide was 0.90 per 1000 PY (8 deaths) in the efavirenz group and 0.18 (1 
death) in the efavirenz-free group. The nine reported suicides were among men; seven were 
white non-Hispanic from the United States and two were Asian from India. Incidence of 
death from suicide, injury or unknown cause in the efavirenz and efavirenz-free groups, 
respectively, was 2.93 and 1.73 per 1000 PY (17 and 7 deaths) among United States 
participants, and 3.58 and 0 per 1000 PY (11 and 0 deaths) among multinational 
participants. Other causes of death (e.g. infection, cancer, or organ failure) occurred with 
similar incidence in the efavirenz and efavirenz-free groups among United States 
participants (5.17 and 5.18 per 1000 PY, respectively); among multinational participants 
incidence of other causes of death was 8.46 and 9.66 per 1000 PY in the efavirenz and 
efavirenz-free groups (Supplement).
Discussion
Among HIV-1-infected treatment-naïve patients from four ACTG studies, the hazard of 
suicidality (suicidal ideation, attempted or completed suicide) was significantly higher with 
a randomly assigned efavirenz-containing regimen, about twice that observed with an 
efavirenz-free regimen. This increased hazard was seen across studies and sensitivity 
analyses. Moreover, eight of nine completed suicides were in the efavirenz group.
In multivariable analyses, factors associated with increased hazard of suicidality were 
random assignment to efavirenz, self-reported history of IDU, and documented psychiatric 
history or recent pre-study psychoactive medication. In some analyses, younger age and 
lower body weight were also associated with increased hazard of suicidality. The efavirenz 
association did not appear to differ substantially by any particular baseline characteristic 
(Supplement), yet the subgroup analyses are limited by small event numbers within groups, 
and have potential for confounding by concurrent cultural and patient characteristics (28).
To our knowledge, this is the first reported analysis to demonstrate a statistically significant 
association between randomly-assigned efavirenz for initial treatment of HIV and suicidal 
thoughts or behavior. A French patient-recall questionnaire showed that 9% of patients 
receiving efavirenz reported emergent suicidal ideation >1 month after treatment initiation 
(29). In contrast, a study of treatment-experienced patients (ALIZE-ANRS 099) did not 
detect an association between randomly assigned efavirenz and depressive disorder (HR, 
1.32; p=0.47), 4 suicide attempts were reported—1/178 in the efavirenz group and 3/177 in 
the protease inhibitor group (30). Extended 4-year follow-up restricted to the ALIZE-ANRS 
099 efavirenz group reported attempted suicide in 3 participants, including 1 suicide death 
after 3 years on-study (31). In HPTN 052, a randomized study of early versus delayed 
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initiation of antiretroviral-therapy for HIV-1-infection, 81% used an initial efavirenz-
containing regimen; as of February 2011 there were 10 deaths in the early group, including 3 
suicides and 3 unknown cause deaths (all 10 were prescribed efavirenz); in the delayed 
group, there were 13 deaths—including 6 unknown cause deaths and 0 suicides (32).
The efavirenz prescribing information describes psychiatric events from two early 
randomized studies (5, 6, 33), with open-label indinavir and double-blinded nelfinavir-
containing comparator regimens, respectively; the frequency of suicidal ideation was 0.7% 
of 1008 patients in the efavirenz group and 0.3% of 635 patients in the efavirenz-free group, 
with nonfatal suicide attempts among 0.5% and 0%, respectively (5). Publicly-available 
medical and statistical review documentation for traditional FDA approval of efavirenz 
states that efavirenz-containing treatment (relative risk=2.1, confidence interval not 
reported) and history of psychiatric disorder (relative risk=4.2) were associated with serious 
nervous system or psychiatric experiences; events included aggravated or severe depression, 
hallucination, suicidal ideation or attempt, seizure, aggressive reaction, paranoid reaction, 
and manic reaction (34); the prescribing information contains comparable qualitative 
statements (5). Similar estimates were identified in the current analysis with respect to 
relative hazard of suicidality. The data presented in the current analysis contribute important 
information on suicidality; with a total of 83 patients with reported suicidality (34 attempted 
or completed suicide).
The overall incidence of suicidality observed here was similar to the 5.4 per 1000 PY 
incidence of depression, attempted or completed suicide reported in an HIV-infected French 
cohort (35). Nonetheless, it remains possible that suicidal ideation was underreported here. 
Secondary analysis of suicidality or fatal injury (substance abuse, homicide, or accident) 
was conducted to help capture deaths possibly related to suicidal behavior; this analysis also 
demonstrated a two-fold increased hazard with efavirenz; consistent with the primary result. 
Death attributed to suicide, injury or unknown cause was reported for 28 participants in the 
efavirenz group and 7 in the efavirenz-free group. Suicide is sometimes misclassified as 
accidental death or unknown cause, and could have been underreported (36, 37).
Combined with a stratified analysis, the four randomized studies presented here provide a 
large and diverse patient population that enhances the strength of our findings. Each study 
had a concurrent efavirenz-free comparison group and patient characteristics were balanced 
through randomization. Patients were followed closely every 2-3 months for a median of 
nearly 3 years, regardless of treatment modification or adverse events. Our primary analyses 
were ITT, an approach supported by the better reporting of harms CONSORT extension 
(38), and results from as-treated and multivariable analyses supported the primary results. 
While several published case reports describe suicidality onset within a month following 
efavirenz initiation (9-13, 15); late onset suicidality has also been documented (14, 34). In 
our analysis, suicidality occurred throughout follow-up, both early and late (Figure 1), 
emphasizing the importance of long-term assessment.
This study has limitations. Three of four trials were open-label, thus suicidality, particularly 
suicidal ideation, may have been susceptible to reporting bias; suicide was listed under post-
marketing experiences in the efavirenz prescribing information prior to the timeframe of 
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these studies (5). There was no standardized questionnaire regarding suicidality or 
depression, such as the Hamilton scale (39), and psychiatric or suicidal history may have 
been under-reported or undisclosed to care providers. Furthermore, patients with psychiatric 
history could have been selectively not referred or recruited to these clinical trials due to 
concerns for potential adverse events. The efavirenz-free comparison arms here included 
two or three nucleosides with or without a protease inhibitor, respectively; efavirenz was not 
compared to another NNRTI or integrase inhibitor in these studies. Occurrence, disclosure 
and method of suicidality may vary by sex, race, and across regions of the world due to 
social, cultural, and economic differences (40-44). This large study included 5332 patients 
enrolled from nine countries; yet small suicidality event numbers limited our ability to 
assess potential differences between countries (Supplement).
Efavirenz is associated with central nervous system side effects and reports of suicidality (5, 
9-17), and there is limited mechanistic evidence linking efavirenz to neurotoxicity (45-48). 
In our analysis, suicidal ideation, suicide attempt, suicide death, and unknown death each 
followed a pattern of greater frequency with efavirenz. The random assignment to efavirenz 
or non-efavirenz therapy increases the likelihood that these results represent a causal 
relationship between efavirenz and suicidality. Given the widespread use of efavirenz and 
severity of this adverse event, the observed increased risk is clinically relevant. Suicidality 
occurred uncommonly, but with increased frequency in patients treated with efavirenz or 
those with a history of psychiatric comorbidities or injection drug use. In general, suicide 
risk factors include, but are not limited to, previous suicide attempt, substance or alcohol 
abuse, fixed hopelessness, agitation, severe depression, anxiety or panic, impulsiveness, 
complete loss of pleasure, uncontrolled pain, and poor social support (40, 49, 50). Care 
should be taken to avoid stigmatization of persons living with HIV and psychiatric 
comorbidities (51-53). When efavirenz is used as a component of antiretroviral therapy there 
should be careful monitoring for exacerbation of depression or evidence of suicidal thoughts 
or behavior.
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Appendix Figure 1. Cumulative incidence of attempted or completed suicide and non-suicide 
death
Appendix Figure 1A (Attempted or completed suicide ITT DSMB)
Appendix Figure 1B (Attempted or completed suicide ITT)
Cumulative incidence of attempted or completed suicide is presented on the left, and 
cumulative incidence of death attributed to causes other than reported suicide (competing 
risk) is presented on the right. Range of y-axis is limited to 0 through 0.10. Gray's test was 
stratified by study. Panel A: follow-up was censored after data safety monitoring board 
recommendations pertaining to the efavirenz comparisons, Panel B: intention-to-treat 
approach, including follow-up from randomization to last on-study contact.
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Figure 1. Cumulative incidence of suicidality and non-suicide death
Figure 1A (Suicidality ITT DSMB)
Figure 1B (Suicidality ITT)
Cumulative incidence of suicidal ideation, attempted, or completed suicide (suicidality) is 
presented on the left, and cumulative incidence of death attributed to causes other than 
reported suicide (competing risk) is presented on the right. Range of y-axis is limited to 0 
through 0.10. Gray's test was stratified by study. Panel A: follow-up was censored after data 
safety monitoring board recommendations pertaining to the efavirenz comparisons, Panel B: 
intention-to-treat approach, including follow-up from randomization to last on-study contact.
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Figure 2. Association between efavirenz and the hazard of suicidality
DSMB= data safety monitoring board, IR=crude incidence rate, PY=person-years, 
CI=confidence interval. Univariate estimated hazard ratios were quantified from a Cox 
model with a Wald CI and p-value, stratified by study, and are plotted on a logarithm scale. 
Panel A: follow-up was censored after data safety monitoring board recommendations 
pertaining to the efavirenz comparisons, Panel B: intention-to-treat approach, including 
follow-up from randomization to last on-study contact.
*p-value for efavirenz association, p-values for interaction with efavirenz are presented for 
study and region
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